AMINOPENTAMIDE

US Previously Marketed

First approved in 1953

Details

Stereochemistry	RACEMIC
Molecular Formula	C19H24N2O
Molecular Weight	296.4067
Optical Activity	( + / - )
Defined Stereocenters	0 / 1
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

CC(CC(C(N)=O)(C1=CC=CC=C1)C2=CC=CC=C2)N(C)C

InChI

InChIKey=NARHAGIVSFTMIG-UHFFFAOYSA-N

InChI=1S/C19H24N2O/c1-15(21(2)3)14-19(18(20)22,16-10-6-4-7-11-16)17-12-8-5-9-13-17/h4-13,15H,14H2,1-3H3,(H2,20,22)

HIDE SMILES / InChI

Molecular Formula	C19H24N2O
Molecular Weight	296.4067
Charge	0
Count

Stereochemistry	RACEMIC
Additional Stereochemistry	No
Defined Stereocenters	0 / 1
E/Z Centers	0
Optical Activity	( + / - )

Description
Sources: https://www.drugs.com/pro/centrine.html | https://www.law.cornell.edu/cfr/text/21/522.62 | http://www.petplace.com/article/drug-library/library/prescription/aminopentamide-centrine

Aminopentamide is a potent antispasmodic agent. As a cholinergic blocking agent for smooth muscle, its action is similar to atropine. Aminopentamide hydrogen sulfate is marketed under the brand name Centrine indicated in the treatment of acute abdominal visceral spasm, pylorospasm or hypertrophic gastritis and associated nausea, vomiting and/or diarrhea of the dogs and cats. Centrine effectively reduces the tone and amplitude of colonic contractions to a greater degree and for a more extended period than does atropine. Centrine effects a reduction in gastric secretion, a decrease in gastric acidity and a marked decrease in gastric motility. Aminopentamide is a nonselective muscarinic cholinergic .

Originator

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
Muscarinic acetylcholine receptor 162 Target ID: CHEMBL2094109 Sources: https://www.drugs.com/pro/centrine.html \| http://veterinarycalendar.dvm360.com/antiemetic-therapy-dogs-and-cats-new-versus-old-proceedings \| https://books.google.ru/books?id=8iwym8Q5XQ8C&pg=PA484&lpg=PA484&dq=aminopentamide retrieved from Canine and Feline Gastroenterology - E-Book By Robert J. Washabau, Michael J. Day, p.484	Antagonist 2849

Conditions

Condition	Modality	Targets	Highest Phase	Product
Hypertrophic gastritis 6 Sources: https://www.drugs.com/pro/centrine.html	Primary		Approved 8583	Centrine Approved Use Centrine is indicated in the treatment of acute abdominal visceral spasm, pylorospasm or hypertrophic gastritis and associated nausea, vomiting and/or diarrhea. Launch Date 1970

Sourcing

Vendor/Aggregator	ID	URL
001 Chemical	DY562581	https://www.001chemical.com/chem/60-46-8
abcr GmbH	AB511594	http://www.abcr.com/shop/en/AB511594
AK Scientific, Inc. (AKSCI)	X4884	http://www.aksci.com/item_detail.php?cat=X4884
Alfa Chemistry	60-46-8	https://www.alfa-chemistry.com/aminopentamide-sulfate-200-mg-cas-60-46-8-item-292915.htm
Alichem	19126227	http://www.alichem.com/en/products/60-46-8.html
Aurora Fine Chemicals LLC	A17.946.078	http://online.aurorafinechemicals.com/info?ID=A17.946.078
BioChemPartner	BCP32413	http://www.biochempartner.com/60-46-8-BCP32413
BLD Pharm	BD114001	http://www.bldpharm.com/products/60-46-8.html
ChemMol	99117809	http://www.chemmol.com/chemmol/99117809.html
Chemspace	CSSB00020675437	https://chem-space.com/CSSB00020675437
eNovation Chemicals	D131710	https://www.enovationchem.com/ProductDetails.asp?ProductID=D131710
LGC Standards	DRE-C10209400	https://www.lgcstandards.com/US/en/p/DRE-C10209400
Molcore	MC562581	https://www.molcore.com/product/60-46-8
Sigma-Aldrich	PH004881_ALDRICH	https://www.sigmaaldrich.com/catalog/product/aldrich/ph004881
Smolecule	S571745	https://www.smolecule.com/products/s571745

PubMed

Title	Date	PubMed
[Broncholytic effect of a new synthetic drugs: aminopentamide].	1957-06	13499735
Some aspects of the pharmacology and clinical application of a parasympatholytic agent, aminopentamide.	1956-09-01	13358891
The pharmacological activity of DL-alpha, alpha-diphenyl, gamma-dimethylaminovaleramide (centrine).	1954-01	13118479

Patents

Sample Use Guides

In Vivo Use Guide

Dogs and cats: Administer by subcutaneous or intramuscular injection every 8 to 12 hours as follows: For animals weighing up to 10 pounds (lbs): 0.1 mg; For animals weighing 11 to 20 lbs: 0.2 mg; For animals weighing 21 to 50 lbs: 0.3 mg; For animals weighing 51 to 100 lbs: 0.4 mg; For animals weighing over 100 lbs: 0.5 mg. Dosage may be gradually increased up to a maximum of five times the suggested dosage. Following parenteral use, dosage may be continued by oral administration of tablets.

Route of Administration: Other

In Vitro Use Guide

A concentration of 0.00005 mg of Aminopentamide per ml of bath fluid was found to reduce the frequency of guinea pig ureteral contractions and a concentration of 0.005 mg/ml virtually stopped contractions.

Substance Class	Chemical Created by `admin` on `Wed Apr 02 06:56:18 GMT 2025` Edited by `admin` on `Wed Apr 02 06:56:18 GMT 2025`
Record UNII	IP1B47L61M
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

DIMEVAMIDE

Preferred Name

English

AMINOPENTAMIDE

Common Name

English

BENZENEACETAMIDE, .ALPHA.-(2-(DIMETHYLAMINO)PROPYL)-.ALPHA.-PHENYL-

Systematic Name

English

VALERAMIDE, 4-(DIMETHYLAMINO)-2,2-DIPHENYL-

Systematic Name

English

.ALPHA.-(2-(DIMETHYLAMINO)PROPYL)-.ALPHA.-PHENYLBENZENEACETAMIDE

Systematic Name

English

AMINOPENTAMIDE [MI]

Common Name

English

NSC-759162

Code

English

4-DIMETHYLAMINO-2,2-DIPHENYLVALERAMIDE

Systematic Name

English

CENTRINE

Brand Name

English

dimevamide [INN]

Common Name

English

Dimevamide [WHO-DD]

Common Name

English

BL-139

Code

English

DIMEVAMIDE [MART.]

Common Name

English

Classification Tree Code System Code

CFR

21 CFR 522.62